A Phase 2 Trial of Ibrutinib and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma
Phase of Trial: Phase II
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Ibrutinib (Primary) ; Nivolumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 17 Mar 2017 Planned primary completion date changed from 1 May 2017 to 31 May 2019.
- 20 Dec 2016 Status changed from not yet recruiting to recruiting.
- 05 Nov 2016 Planned primary completion date changed from 1 Apr 2020 to 1 May 2017.